title: Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants.
abstract: BACKGROUND
  Although respiratory syncytial virus (RSV) infection is known to cause severe pulmonary infections in bone marrow transplant recipients, less is known concerning its clinical course, diagnosis, and treatment in solid organ transplant recipients.
  
  
  METHODS
  We have conducted a retrospective review of seven cases of RSV infection in adult recipients of solid organ transplants. Four patients received lungs, two received kidneys, and one received a heart.
  
  
  RESULTS
  The most common presenting complaints were dyspnea (100%), cough (86%), and purulent sputum (57%). Physical findings included fever (43%), rales (100%), and wheezing (29%). Admission studies were significant for leukocytosis (29%), a left shift in the white blood cell differential (86%), and hypoxemia (mean PaO2 = 64). Chest radiographs were unchanged in 29% and showed infiltrates that were bilateral in 43% and unilateral in 29%. Pulmonary function tests in lung transplant recipients showed a mean fall in forced expiratory volume in 1 second of 26% and a fall in diffusion capacity for carbon monoxide of 24%. Five patients were treated with aerosolized ribavirin. Adverse events associated with treatment included wheezing (80%) and mild dyspnea (20%). The conditions of three of five treated patients were believed by their physicians to have improved 7 days after the initiation of therapy. One of the five treated patients died, and both untreated patients survived.
  
  
  CONCLUSIONS
  RSV infection in this population has an extremely variable severity and clinical course, usually dominated by lower respiratory symptoms and obstructive airway disease. Ribavirin therapy is well tolerated, but its efficacy remains unknown.
authors.affiliation: Lung Transplant Program, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: S
authors.initials: S
authors.lastname: Krinzman
authors.forename: N
authors.initials: N
authors.lastname: Basgoz
authors.forename: R
authors.initials: R
authors.lastname: Kradin
authors.forename: J A
authors.initials: JA
authors.lastname: Shepard
authors.forename: D B
authors.initials: DB
authors.lastname: Flieder
authors.forename: C D
authors.initials: CD
authors.lastname: Wright
authors.forename: J C
authors.initials: JC
authors.lastname: Wain
authors.forename: L C
authors.initials: LC
authors.lastname: Ginns
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000209:etiology* / Q000821:virology; D016040:Lung Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D011859:Radiography; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000635:transmission*; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin